New hope for tough pancreatic cancers: can immunotherapy boost chemo?
NCT ID NCT03983057
Summary
This study tested if adding an immunotherapy drug (Anti-PD-1 antibody) to standard chemotherapy (modified-FOLFIRINOX) could help patients with borderline or locally advanced pancreatic cancer. It involved 392 participants who were randomly assigned to receive either the standard chemo alone or the chemo plus immunotherapy combination. The main goal was to see if the combination could better control the cancer, delay its progression, and help more patients become eligible for surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.